A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine using Olanzapine as an Active Control in Subjects Diagnosed with Schizophrenia who Completed Protocol P05688 (formerly 041038) (Phase 3B, Protocol P05689 [forme
Read time: 1 mins
Last updated:10th Jun 2013
The primary objective of this trial is to evaluate the long-term safety of 2.5 and 5 mg BID asenapine in schizophrenia subjects.
|Study start date||2013-06-10|